CervoMed (CRVO) Return on Capital Employed (2011 - 2025)
CervoMed (CRVO) posted Return on Capital Employed of 128.1% for Q4 2025, down 149.2% sequentially from 51.4% in Q1 2025, and down 8480.0% YoY from 1.53% in Q4 2024.
CervoMed (CRVO) Return on Capital Employed (2011 - 2025) Analysis & Trends
CervoMed has reported Return on Capital Employed for 14 years, with the latest figure at 128.1% in Q4 2025.
- Quarterly Return on Capital Employed fell 8480.0% year-over-year to 128.1% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 128.1% (down 8480.0% YoY) and the FY2025 annual result came in at 99.9%, down 1942.0% from the prior year.
- Return on Capital Employed slipped to 128.1% in Q4 2025 per CRVO's latest filing, from 51.4% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 26.44% in Q3 2024 and troughed at 190.29% in Q1 2023.
- A 5-year average of 73.59% and a median of 66.43% in 2021 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed slumped 11534 bps in 2023, then soared 8990 bps in 2024.
- Over 5 years, Return on Capital Employed stood at 62.8% in 2021, then retreated by 12 bps to 70.07% in 2022, then dropped by 2 bps to 71.57% in 2023, then surged by 40 bps to 43.29% in 2024, then slumped by 196 bps to 128.1% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 128.1%, 51.4%, and 43.29% for Q4 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | CervoMed | 26.64 Mn | 26.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -128.10% |
| Mar 31, 2025 | -51.40% |
| Dec 31, 2024 | -43.29% |
| Sep 30, 2024 | -26.44% |
| Jun 30, 2024 | -35.26% |
| Mar 31, 2024 | -100.68% |
| Dec 31, 2023 | -71.57% |
| Sep 30, 2023 | -82.74% |
| Jun 30, 2023 | -125.16% |
| Mar 31, 2023 | -190.29% |
| Dec 31, 2022 | -70.07% |
| Sep 30, 2022 | -51.68% |
| Jun 30, 2022 | -79.74% |
| Mar 31, 2022 | -74.95% |
| Dec 31, 2021 | -62.80% |
| Sep 30, 2021 | -54.16% |
| Jun 30, 2021 | -34.14% |
| Mar 31, 2021 | -42.24% |
| Dec 31, 2020 | -36.75% |
| Sep 30, 2020 | -28.58% |